Skip to content
OpenCapital
Get started

Zymeworks ZYME Debt Securities And Equity Securities Without Readily Determinable Fair Value, Cost

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept zyme:DebtSecuritiesAndEquitySecuritiesWithoutReadilyDeterminableFairValueCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Zymeworks's debt securities and equity securities without readily determinable fair value, cost?
Zymeworks (ZYME) reported debt securities and equity securities without readily determinable fair value, cost of $39.05M in Q1 2026.
How has Zymeworks's debt securities and equity securities without readily determinable fair value, cost changed year-over-year?
Zymeworks's debt securities and equity securities without readily determinable fair value, cost decreased by 30.5% year-over-year, from $56.21M to $39.05M.
What is the long-term trend for Zymeworks's debt securities and equity securities without readily determinable fair value, cost?
Over 2 years (2023 to 2025), Zymeworks's debt securities and equity securities without readily determinable fair value, cost has grown at a -29.1% compound annual growth rate (CAGR), from $82.26M to $41.39M.